Abasaglar ® (basal insulin glargine)

How to Switch from Insulin Glargine 300 units/mL to Abasaglar® (insulin glargine)?

If transitioning patients from Insulin Glargine 300 units/mL (IG-300) to Abasaglar, the recommended initial Abasaglar dose is approximately 80% of the dose of IG-300.

UK_cFAQ_BIV039_GLARGINE_300
UK_cFAQ_BIV039_GLARGINE_300
en-GB

Information from the Label

Abasaglar and Toujeo (insulin glargine 300 units/ml; IG-300) are not bioequivalent and are not directly interchangeable.

When transitioning from IG-300, Abasaglar shoud be reduced by approximately 20% to decrease the risk of hypoglycemia.

During the first weeks, an increase in mealtime insulin should, at least partially, compensated this reduction of basal insulin.

After this period, the regimen should be adjusted individually.1

Dosing in Phase 3 Studies of Insulin Glargine 300 Units/mL

A phase 3a study compared IG-300 with insulin glargine 100 units/mL (IG-100) in patients with type 1 diabetes mellitus.

Patients needed 18% more IG-300 than those who received IG-100 to achieve a similar mean reduction in glycated hemoglobin (HbA1c).2

3 phase 3a studies compared IG-300 with IG-100 in patients with ype 2 diabetes mellitus.

Patients needed 10% to 17% more IG-300 than those who received IG-100 to achieve similar levels of glycemic control.3-5

References

1Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38(12):2217-2225. http://dx.doi.org/10.2337/dc15-0249

3Riddle MC, Bolli GB, Ziemen M, et al; EDITION 1 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755-2762. http://dx.doi.org/10.2337/dc14-0991

4Yki-Järvinen H, Bergenstal R, Ziemen M, et al; EDITION 2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37(12):3235-3243. http://dx.doi.org/10.2337/dc14-0990

5Bolli GB, Riddle MC, Bergenstal RM, et al; EDITION 3 Study Investigators. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17(4):386-394. http://dx.doi.org/10.1111/dom.12438

Date of Last Review: July 10, 2019


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request